These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27416882)

  • 61. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
    Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
    Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
    Guan Z; Xu B; DeSilvio ML; Shen Z; Arpornwirat W; Tong Z; Lorvidhaya V; Jiang Z; Yang J; Makhson A; Leung WL; Russo MW; Newstat B; Wang L; Chen G; Oliva C; Gomez H
    J Clin Oncol; 2013 Jun; 31(16):1947-53. PubMed ID: 23509322
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
    Miller K; Wang M; Gralow J; Dickler M; Cobleigh M; Perez EA; Shenkier T; Cella D; Davidson NE
    N Engl J Med; 2007 Dec; 357(26):2666-76. PubMed ID: 18160686
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer.
    Inoue K; Kuroi K; Shimizu S; Rai Y; Aogi K; Masuda N; Nakayama T; Iwata H; Nishimura Y; Armour A; Sasaki Y
    Int J Clin Oncol; 2015 Dec; 20(6):1102-9. PubMed ID: 25967286
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
    Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD
    Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer.
    Seidman AD; Conlin AK; Bach A; Moynahan ME; Lake D; Forero A; Wright GS; Hackney MH; Clawson A; Norton L; Hudis CA
    Clin Breast Cancer; 2013 Aug; 13(4):239-246.e1. PubMed ID: 23829890
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
    Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
    Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial.
    Smith I; Pierga JY; Biganzoli L; Cortes-Funes H; Thomssen C; Saracchini S; Nisenbaum B; Pelaez I; Duenne AA; Pritchard KI
    Breast Cancer Res Treat; 2011 Nov; 130(1):133-43. PubMed ID: 21830015
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients.
    Ozdemir N; Aksoy S; Sendur MA; Akinci MB; Yazici O; Budakoglu B; Abali H; Oksuzoglu B; Zengin N
    J BUON; 2013; 18(4):831-7. PubMed ID: 24344005
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).
    Claessens AKM; Bos MEMM; Lopez-Yurda M; Bouma JM; Rademaker-Lakhai JM; Honkoop AH; de Graaf H; van Druten E; van Warmerdam LJC; van der Sangen MJC; Tjan-Heijnen VCG; Erdkamp FLG;
    Breast Cancer Res Treat; 2018 Nov; 172(2):413-423. PubMed ID: 30121808
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A Real-World Retrospective Cohort Study of Combined Therapy with Bevacizumab and Paclitaxel in Japanese Patients with Metastatic Breast Cancer.
    Yamada H; Inoue K; Nagai SE; Nakai M; Arisawa F; Ueda H; Saito T; Ninomiya J; Kuroda T; Sakurai T; Kodama H; Kimizuka K; Hata S; Kai T; Kurosumi M;
    J Nippon Med Sch; 2017; 84(5):215-223. PubMed ID: 29142182
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study.
    Cortot AB; Audigier-Valette C; Molinier O; Le Moulec S; Barlesi F; Zalcman G; Dumont P; Pouessel D; Poulet C; Fontaine-Delaruelle C; Hiret S; Dixmier A; Renault PA; Becht C; Raffy O; Dayen C; Mazieres J; Pichon E; Langlais A; Morin F; Moro-Sibilot D; Besse B
    Eur J Cancer; 2020 May; 131():27-36. PubMed ID: 32276179
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study.
    Xu BH; Jiang ZF; Shen ZZ; Guan ZZ; Chen ZD; Cheng Y; Zheng H; Jiang J; Wang XJ; Tong ZS; Qin SK; Luo Y; Yao M; Wang LW; He J
    Chin Med J (Engl); 2012 Mar; 125(5):764-9. PubMed ID: 22490570
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies.
    Yamamoto Y; Yamashiro H; Schneeweiss A; Müller V; Gluz O; Klare P; Aktas B; Magdolna D; Büdi L; Pikó B; Mangel L; Toi M; Morita S; Ohno S
    Breast Cancer; 2023 Jan; 30(1):88-100. PubMed ID: 36057014
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
    de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
    Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study.
    Jankowitz RC; Abraham J; Tan AR; Limentani SA; Tierno MB; Adamson LM; Buyse M; Wolmark N; Jacobs SA
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1205-12. PubMed ID: 24077916
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer.
    Claessens AKM; Erdkamp FLG; Lopez-Yurda M; Bouma JM; Rademaker-Lakhai JM; Honkoop AH; de Graaf H; Tjan-Heijnen VCG; Bos MEMM;
    Acta Oncol; 2020 Jun; 59(6):713-722. PubMed ID: 32141389
    [No Abstract]   [Full Text] [Related]  

  • 78. An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.
    Cardoso F; Canon JL; Amadori D; Aldrighetti D; Machiels JP; Bouko Y; Verkh L; Usari T; Kern KA; Giorgetti C; Dirix L
    Breast; 2012 Dec; 21(6):716-23. PubMed ID: 23022045
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.
    Holmes FA; Valero V; Walters RS; Theriault RL; Booser DJ; Gibbs H; Fraschini G; Buzdar AU; Willey J; Frye D; Asmar L; Hortobagyi GN
    Ann Oncol; 1999 Apr; 10(4):403-11. PubMed ID: 10370782
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab.
    Pizzuti L; Sergi D; Sperduti I; Lauro LD; Mazzotta M; Botti C; Izzo F; Marchetti L; Tomao S; Marchetti P; Natoli C; Grassadonia A; Gamucci T; Mentuccia L; Magnolfi E; Vaccaro A; Cassano A; Rossi E; Botticelli A; Sini V; Sarobba MG; Fabbri MA; Moscetti L; Astone A; Michelotti A; De Angelis C; Bertolini I; Angelini F; Ciliberto G; Maugeri-Saccà M; Giordano A; Barba M; Vici P
    Cancer Biol Ther; 2018 Apr; 19(4):328-334. PubMed ID: 29336662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.